

WELCOME TO SKYRIZI COMPLETE. RESOURCES DESIGNED AROUND YOU.



You may have questions about SKYRIZI. That's why Skyrizi Complete is here to help:

- Make sense of your insurance coverage
- Provide support to help you prepare for your appointments
- Identify ways you may be able to save on SKYRIZI
- Provide supplemental self-injection training, if needed

Your Skyrizi Complete Nurse Ambassador* is committed to helping you understand your treatment, answering your questions, and supporting you to achieve your personal goals while on SKYRIZI. Your Ambassador will be there every step of the way, for as long as you need.

You've signed up for Skyrizi Complete. Here's what to do next:

1

Before you leave the office, ask your health care professional which Specialty Pharmacy your prescription is being sent to and write down its number below. This pharmacy will help you plan your SKYRIZI delivery and may follow up with you.

SPECIALTY PHARMACY: _____ **PHONE:** _____

2

Expect a call from your Ambassador within 1 business day (the call may come from any area code). They'll help you navigate the prescription process and help you start and stay on track with your prescribed treatment plan.

For questions, or if you have not yet connected with your Nurse Ambassador, please call **1.866.SKYRIZI (1.866.759.7494)**.

Skyrizi[®] COMPLETE

*Nurse Ambassadors are provided by AbbVie and do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

The categories of personal information collected in this Enrollment and Prescription Form include contact, insurance, prescription, and medical history information. The personal information collected will be used to provide and manage the Skyrizi Complete program and to perform research and analytics on a de-identified basis. For more information about the categories of personal information collected by AbbVie and the purposes for which AbbVie uses personal information, visit www.abbvie.com/privacy.html.

Please see [Uses and Important Safety Information](#) on page 2.

Please see full [Prescribing Information](#), including [Medication Guide](#), or visit https://www.rxabbvie.com/pdf/skyrizi_pi.pdf


Skyrizi[®]
risankizumab-rzaa

Uses and Important Safety Information About SKYRIZI® (risankizumab-rzaa)¹

SKYRIZI Uses¹

SKYRIZI® (risankizumab-rzaa) is a prescription medicine used to treat adults:

- with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
- with active psoriatic arthritis (PsA).

Important Safety Information¹

What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

- Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
 - fainting, dizziness, feeling lightheaded (low blood pressure)
 - swelling of your face, eyelids, lips, mouth, tongue, or throat
 - trouble breathing or throat tightness
 - chest tightness
 - skin rash, hives
 - itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

- Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
 - fever, sweats, or chills
 - cough
 - shortness of breath
 - blood in your mucus (phlegm)
 - muscle aches
 - warm, red, or painful skin or sores on your body different from your psoriasis
 - weight loss
 - diarrhea or stomach pain
 - burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “What is the most important information I should know about SKYRIZI?”
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
- are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See “What is the most important information I should know about SKYRIZI?”

The most common side effects of SKYRIZI include upper respiratory infections, feeling tired, fungal skin infections, headache, and injection site reactions.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help.

Visit AbbVie.com/myAbbVieAssist to learn more.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.

Please see full **Prescribing Information**, including **Medication Guide**, or visit https://www.rxabbvie.com/pdf/skyrizi_pi.pdf

Enrollment and Prescription Form

SPSA-020121-A12

FAXING INSTRUCTIONS:

1. Fax to Skyrizi Complete (1.678.727.0690)
 2. Fax to the patient's preferred Specialty Pharmacy
- Questions? Call 1.866.759.7494

Sections in **BLUE** (1, 2, 3, 4) are necessary for enrollment into Skyrizi Complete. Required fields are marked with an asterisk (*).

The health care professional (HCP) and the patient or legally authorized person should fill out this form completely before leaving the office.

1 PATIENT'S INFORMATION - To be completed by patient or legally authorized person. Please print clearly.

First Name*: _____ Last Name*: _____ Date of Birth: ____/____/____ Gender (check one): ☐ M ☐ F
 Address*: _____ City*: _____ State*: _____ ZIP*: _____
 Home Phone*: _____ Mobile Phone: _____ Email Address*: _____ ☐ Spanish interpreter needed

☐ I consent to receive recurring text messages from AbbVie, including service updates, medication reminders and marketing messages, to the above mobile number. Message and data rates may apply. My consent is not a condition of receiving goods or services. I can reply HELP for help. I can text STOP to unsubscribe any time. [View full Terms and Conditions.](#)

Best Time to Call (Monday-Friday): ☐ Anytime ☐ Morning ☐ Afternoon ☐ Evening

When did you start on treatment?* ☐ Not Yet Started ☐ 0-3 Months Ago ☐ 4-6 Months Ago ☐ 7-12 Months Ago ☐ Over 12 Months Ago

By enrolling, you may receive your own Nurse Ambassador provided by AbbVie. Ambassadors do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals. To learn about AbbVie's privacy practices and your privacy choices, visit www.abbvie.com/privacy.html.

☐ I would like to receive news and updates about AbbVie's products, clinical trials, research opportunities, programs, and other information that may be of interest to me.

2 INSURANCE INFORMATION ☐ Check box if you will attach a copy of your Insurance Cards. Please also provide supplemental insurance.

Beneficiary/Cardholder Name: _____ Prescription Insurance: _____
 Medical Insurance: _____ Rx Group #: _____
 Medical Insurance ID #: _____ Rx ID #: _____
 Group #: _____ Rx Bin #: _____ Rx PCN #: _____

FOR HEALTH CARE PROVIDER USE ONLY

3 DIAGNOSIS* ☐ Plaque Psoriasis (Ps) ☐ Psoriatic Arthritis (PsA) ICD-10: _____ Date of Diagnosis: ____/____/____

4 PRESCRIBER INFORMATION I would like to receive a copy: ☐ Benefits Verification Summary ☐ Prior Authorization Form

Prescriber's Name (First, Last)*: _____ Office Phone*: _____ Address*: _____
 Office Contact Name: _____ City*: _____ State*: _____ ZIP*: _____
 NPI #: _____ Office Fax*: _____ Email: _____

5 CLINICAL INFORMATION

Prior Therapies: _____ Concomitant Medications: _____ TB Test (Date): ____/____/____ ☐ Pos ☐ Neg
 Weight: _____ Height: _____
 Drug Allergies: _____ Fax any necessary clinical/office notes to the preferred Specialty Pharmacy only.
 Plaque Psoriasis BSA%: _____

6 INJECTION TRAINING ☐ I request supplemental injection training and/or administration, if needed, for this patient. Order valid for up to one year. Fill out and sign pharmacy prescription below.

7 PHARMACY PRESCRIPTION - OPTIONAL - Fill out and sign corresponding prescription below.

Patient's preferred Specialty Pharmacy: _____ ☐ Check if faxed to Specialty Pharmacy

☐ Plaque Psoriasis (Ps) ☐ Psoriatic Arthritis (PsA)

Choose one SKYRIZI presentation:

- ☐ SKYRIZI PEN 150 mg
☐ SKYRIZI SYRINGE 150 mg

Check appropriate boxes to indicate quantity to dispense (one dose each) and directions:

- ☐ Initiation at Week 0: Inject 150 mg SC
☐ Initiation at Week 4: Inject 150 mg SC
☐ Inject 150 mg SC every 12 weeks thereafter
 Refills: _____

PRESCRIBER CERTIFICATION: I certify that the above therapy is medically necessary and that the information provided is accurate to the best of my knowledge. I certify that I am the prescriber who has prescribed SKYRIZI to the previously identified patient and that I provided the patient with a description of the Skyrizi Complete patient support program. I authorize Skyrizi Complete to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy designated by the patient utilizing their benefit plan (if applicable).

Prescriber's Signature: (REQUIRED) X _____ Date: ____/____/____

8 SKYRIZI SHIPPING PREFERENCES Date needed: ____/____/____ First Dose Address: ☐ Prescriber ☐ Patient Follow-Up Doses Address: ☐ Prescriber ☐ Patient

9 SKYRIZI COMPLETE PRESCRIPTION - required in the event a commercially insured patient with a valid Rx for SKYRIZI experiences an insurance access challenge.

See Program Terms and Conditions on reverse side. Please complete the full form as well as this section and sign below. **Prescription to be filled through an AbbVie-authorized pharmacy.** I understand that faxing this form to Skyrizi Complete will result in an original copy being simultaneously transmitted to the AbbVie-authorized pharmacy under this section.

Choose one SKYRIZI presentation:

- ☐ SKYRIZI PEN 150 mg
☐ SKYRIZI SYRINGE 150 mg

Inject 150 mg SC at Week 0, Week 4, and every 12 weeks thereafter

Quantity: 1 dose of 150 mg

Refills: _____

PRESCRIBER CERTIFICATION: I certify that the above therapy is medically necessary and that the information provided is accurate to the best of my knowledge. I certify that I am the prescriber who has prescribed SKYRIZI to the previously identified patient and that I provided the patient with a description of the Skyrizi Complete patient support program. I authorize Skyrizi Complete to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy. I understand that the no charge resource through Skyrizi Complete may support patients who are experiencing an insurance access challenge for SKYRIZI until coverage is obtained, and I confirm that I will support the above-identified patient in seeking to secure such coverage as I deem appropriate. I certify that I will not seek reimbursement from any third party payor for any no charge product dispensed by an AbbVie authorized pharmacy.

Prescriber's Signature: (REQUIRED) X _____ Date: ____/____/____

IMPORTANT INFORMATION: By submitting this form you are referring the above patient to AbbVie's patient support program to determine eligibility and receive support related to an AbbVie product. AbbVie, its affiliates, collaborators and agents will use the information collected about you and your patient to provide the patient support and perform research and analytics, on a de-identified basis, for management of the program. For more information about the categories of personal information collected by AbbVie and the purposes for which AbbVie uses personal information, visit www.abbvie.com/privacy.html. Please share this information with your patient.

Please see **Important Safety Information and full Indication** on page 4. Please see full **Prescribing Information**.

Indications and Important Safety Information¹

SKYRIZI Indications¹

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

Important Safety Information¹

Hypersensitivity Reactions

SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

SKYRIZI COMPLETE PRESCRIPTION TERMS & CONDITIONS

Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI® (risankizumab-rzaa) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.

Please see full **Prescribing Information**.

abbvie

©2021 AbbVie Inc. North Chicago, IL 60064 US-SKZR-210008 November 2021

Skyrizi[®]
risankizumab-rzaa